AL-78898A

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
AL-78898A

GtoPdb Ligand ID: 9219

Synonyms: 4(1MeW) [2] | POT-4

Compound class: Peptide

Comment: AL-78898A is an investigational analogue of compstatin [2], which acts as an irreversible inhibitor of complement component 3 (C3). C3 inhibitors are being actively investigated for clinical potential in inflammatory and degenerative diseases [1].

No information available.

No information available.

Summary of Clinical Use
AL-78898A (POT4) has been investigated i Phase 2 clinical trial for neovascular age-related macular degeneration (AMD). Click here to link to ClinicalTrials.gov's list of AL-78898A/POT-4 trials. See F1000Prime Rep. 2014; 6: 29 (Advances in the management of macular degeneration) for a review of recent research and development in this field.

Summary of Clinical Use

AL-78898A (POT4) has been investigated i Phase 2 clinical trial for neovascular age-related macular degeneration (AMD). Click here to link to ClinicalTrials.gov's list of AL-78898A/POT-4 trials. See F1000Prime Rep. 2014; 6: 29 (Advances in the management of macular degeneration) for a review of recent research and development in this field.

Mechanism Of Action and Pharmacodynamic Effects
Prevents activation of C3, the central component mediating activation of the classical, alternative, and lectin pathways of complement activation.

Mechanism Of Action and Pharmacodynamic Effects

Prevents activation of C3, the central component mediating activation of the classical, alternative, and lectin pathways of complement activation.